Display options
Cite
Silva JH, Sá BC, Avila AL, et al. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo). 2011;66(3):493-9doi: 10.1590/s1807-59322011000300023.
Silva, J. H., Sá, B. C., Avila, A. L., Landman, G., & Duprat Neto, J. P. (2011). Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo, Brazil), 66(3), 493-9. https://doi.org/10.1590/s1807-59322011000300023
Silva, Juliana Hypólito, et al. "Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article." Clinics (Sao Paulo, Brazil) vol. 66,3 (2011): 493-9. doi: https://doi.org/10.1590/s1807-59322011000300023
Silva JH, Sá BC, Avila AL, Landman G, Duprat Neto JP. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo). 2011;66(3):493-9. doi: 10.1590/s1807-59322011000300023. PMID: 21552679; PMCID: PMC3072014.
Copy Download .nbib Format: NLM
Share it on

Clinics (Sao Paulo). 2011;66(3):493-9. doi: 10.1590/s1807-59322011000300023.

Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article.

Clinics (Sao Paulo, Brazil)

Juliana Hypólito Silva, B C de Sá, Alexandre Leon Ribeiro de Avila, Gilles Landman, João Pedreira Duprat Neto

Affiliations

  1. Oncology School Celestino Bourroul, Hospital AC Camargo, São Paulo, SP, Brazil.

PMID: 21552679 PMCID: PMC3072014 DOI: 10.1590/s1807-59322011000300023

Abstract

Atypical Mole Syndrome is the most important phenotypic risk factor for developing cutaneous melanoma, a malignancy that accounts for about 80% of deaths from skin cancer. Because the diagnosis of melanoma at an early stage is of great prognostic relevance, the identification of Atypical Mole Syndrome carriers is essential, as well as the creation of recommended preventative measures that must be taken by these patients.

References

  1. Dermatol Ther. 2006 Jan-Feb;19(1):1-8 - PubMed
  2. Lancet. 1983 Nov 5;2(8358):1076-7 - PubMed
  3. Pathology. 1985 Apr;17(2):291-7 - PubMed
  4. Clin Dermatol. 2009 Jan-Feb;27(1):103-15 - PubMed
  5. JAMA. 1992 Sep 9;268(10):1314-9 - PubMed
  6. J Clin Oncol. 2009 Dec 20;27(36):6199-206 - PubMed
  7. J Am Acad Dermatol. 1987 Oct;17(4):584-91 - PubMed
  8. Eur J Hum Genet. 2008 Sep;16(9):1135-41 - PubMed
  9. J Am Acad Dermatol. 2000 Sep;43(3):467-76 - PubMed
  10. N Engl J Med. 2004 Sep 2;351(10):998-1012 - PubMed
  11. Cancer. 1994 Dec 15;74(12):3118-25 - PubMed
  12. Eur J Cancer. 2005 Jan;41(1):28-44 - PubMed
  13. Edinb Med Surg J. 1820 Oct 1;16(65):562-565 - PubMed
  14. Br Med J (Clin Res Ed). 1984 Jan 14;288(6411):99-102 - PubMed
  15. J Am Acad Dermatol. 1990 Nov;23(5 Pt 1):858-62 - PubMed
  16. Clin Exp Dermatol. 2005 Jan;30(1):68-70 - PubMed
  17. Arch Dermatol. 2005 Aug;141(8):998-1006 - PubMed
  18. Hematol Oncol Clin North Am. 2009 Jun;23(3):481-500, viii - PubMed
  19. J Invest Dermatol. 1993 Mar;100(3):350S-355S - PubMed
  20. J Am Acad Dermatol. 1995 Mar;32(3):479-94 - PubMed
  21. Lancet. 1988 Feb 13;1(8581):352-3 - PubMed
  22. J Am Acad Dermatol. 1986 May;14(5 Pt 1):857-60 - PubMed
  23. J Am Acad Dermatol. 2007 May;56(5):759-67 - PubMed
  24. J Invest Dermatol. 1996 Jun;106(6):1198-202 - PubMed
  25. Arch Dermatol. 2003 Dec;139(12):1620-4; discussion 1624 - PubMed
  26. Hum Pathol. 1984 Dec;15(12):1147-65 - PubMed
  27. Cancer Res. 1986 Feb;46(2):1005-9 - PubMed
  28. Dermatology. 2007;214(1):3-5 - PubMed
  29. Eur J Dermatol. 2006 Sep-Oct;16(5):479-93 - PubMed
  30. Lancet. 2005 Feb 19-25;365(9460):687-701 - PubMed
  31. J Am Acad Dermatol. 1993 Dec;29(6):989-96 - PubMed
  32. Curr Opin Oncol. 2006 Mar;18(2):173-9 - PubMed
  33. Arch Dermatol. 2000 Jul;136(7):915-21 - PubMed
  34. Dermatol Clin. 1985 Apr;3(2):225-37 - PubMed
  35. Isr Med Assoc J. 2007 Oct;9(10):708-12 - PubMed
  36. N Engl J Med. 2006 Jul 6;355(1):51-65 - PubMed
  37. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):889-94 - PubMed
  38. J Med Genet. 1978 Oct;15(5):352-6 - PubMed
  39. Clin Dermatol. 2009 Jan-Feb;27(1):46-52 - PubMed
  40. J Am Acad Dermatol. 2003 May;48(5):663-71 - PubMed
  41. Ophthalmology. 1986 May;93(5):661-5 - PubMed
  42. Eur J Cancer Prev. 2004 Apr;13(2):133-8 - PubMed
  43. J Clin Oncol. 2001 Aug 15;19(16):3635-48 - PubMed
  44. Cancer. 1989 Jan 15;63(2):386-9 - PubMed
  45. N Engl J Med. 2003 Dec 4;349(23):2233-40 - PubMed
  46. J Am Acad Dermatol. 1987 Oct;17(4):571-83 - PubMed
  47. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2384-90 - PubMed
  48. Arch Dermatol. 2001 Dec;137(12):1583-9 - PubMed
  49. J Am Acad Dermatol. 2004 May;50(5):683-9 - PubMed
  50. Arch Dermatol. 1978 May;114(5):732-8 - PubMed
  51. J Am Acad Dermatol. 1990 Jan;22(1):117-8 - PubMed
  52. J Am Acad Dermatol. 1993 Jul;29(1):51-7 - PubMed
  53. Dermatol Clin. 2009 Apr;27(2):205-14, viii - PubMed
  54. Dermatol Ther. 2006 Jan-Feb;19(1):32-9 - PubMed

MeSH terms

Publication Types